Sugi Predict

Sugi Predict / Compounds / SCHEMBL282685

SCHEMBL282685

SCHEMBL282685

NC(=O)c1cccc([N+](=O)[O-])c1C(=O)O

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 2/20 0.60
▸ L3MBTL1 Q9Y468 1/20 0.60
▸ TSHR P16473 1/20 0.56
▸ CTSD P07339 1/20 0.47
▸ TP53 P04637 1/20 0.47
▸ ALDH1A1 P00352 3/20 0.46
▸ POLB P06746 1/20 0.46
▸ GPR35 Q9HC97 1/20 0.46
▸ MEN1 O00255 3/20 0.44
▸ KMT2A Q03164 3/20 0.44
▸ MAPT P10636 2/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ KDM4E B2RXH2 2/20 0.43
▸ GAA P10253 1/20 0.43
▸ LMNA P02545 1/20 0.42
▸ DNA2 P51530 1/20 0.42
▸ CASP6 P55212 1/20 0.42
▸ CTDSP1 Q9GZU7 1/20 0.42
▸ CDC7 O00311 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL7650734 0.98 TDP1 (0.58) TDP1L3MBTL1TSHRCTSDTP53
SCHEMBL1315874 0.89 TDP1 (0.50) TDP1L3MBTL1TSHRCTSDALDH1A1
Methane SCHEMBL28307885 0.88 TDP1 (0.49) TDP1L3MBTL1TSHRCTSDALDH1A1
SCHEMBL15869336 0.87 TDP1 (0.66) TDP1L3MBTL1TSHRCTSDTP53
SCHEMBL304456 0.87 TDP1 (0.66) TDP1L3MBTL1TSHRCTSDTP53
SCHEMBL29351965 0.87 TDP1 (0.66) TDP1L3MBTL1TSHRCTSDTP53
SCHEMBL282684 0.86 TSHR (0.60) TDP1L3MBTL1TSHRCTSDALDH1A1
Water SCHEMBL22463120 0.86 TDP1 (0.64) TDP1L3MBTL1TSHRCTSDTP53
SCHEMBL22463128 0.86 TDP1 (0.64) TDP1L3MBTL1TSHRCTSDTP53
Ammonia Solution, Strong SCHEMBL5572312 0.86 TDP1 (0.64) TDP1L3MBTL1TSHRCTSDTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109042680-A A kind of novel agricultural insecticide composition and preparation method thereof and application method 马骏 2018-12-21 — — CN claimed
CN-100456398-C Electrolyte for driving electrolytic capacitor and electrolytic capacitor RUBYCON CORP (JP) 2009-01-28 — — CN claimed
CN-1529892-A Electrolyte for driving electrolytic capacitor and electrolytic capacitor 如碧空株式会社 2004-09-15 — — CN claimed
CN-119638583-A Production process of 2-amino-6-nitrobenzoic acid 山东极地医药科技有限公司 2025-03-18 — — CN disclosed
US-11820720-B2 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deuteropiperidine-2,6-dione derivatives and compositions comprising and methods of using the same SALARIUS PHARMACEUTICALS, INC. (US) 2023-11-21 — — US disclosed
US-11733233-B2 Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases CELGENE CORPORATION (US) 2023-08-22 — — US disclosed
US-11419861-B2 Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases CELGENE CORPORATION (US) 2022-08-23 — — US disclosed
US-20220003749-A1 METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS CELGENE CORPORATION (US) 2022-01-06 — — US disclosed
EP-3077548-B1 METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS CELGENE CORP (US) 2021-11-10 — — EP disclosed
EP-3827836-A1 COMPOSITIONS AND METHODS FOR INDUCING CONFORMATIONAL CHANGES IN CEREBLON AND OTHER E3 UBIQUITIN LIGASES Celgene Corporation (US) 2021-06-02 — — EP disclosed
US-10996215-B2 Methods for determining drug efficacy for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancers CELGENE CORPORATION (US) 2021-05-04 — — US disclosed
EP-0841924-B1 BENZIMIDAZOLE COMPOUNDS UNIV NEWCASTLE VENTURES LTD (GB) 2002-10-02 — — EP disclosed
US-6310082-B1 PHARMACEUTICAL COMPOSITION COMPRISING EFFECTIVE POLY(ADP-RIBOSE)POLYMERASE ENZYME INHIBITING AMOUNT OF BENZIMIDAZOLE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT AND/OR PRO-DRUG FORM THEREOF, WITH ACCEPTABLE CARRIER NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) 2001-10-30 — — US disclosed
EP-1091958-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2001-04-18 — — EP disclosed
US-6100283-A PRODRUG PHOSPHATE DERIVATIVE FOR POLY (ADP-RIBOSE) POLYMERASE ENZYME INHIBITOR FOR ADMINISTERING IN CONJUNCTION WITH ANTITUMOR DRUG OR RADIOTHERAPY NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) 2000-08-08 — — US disclosed
WO-2000001692-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2000-01-13 — — WO disclosed
CN-1195985-A Benzimidazole compounds UNIV NEWCASTLE VENTURES LTD (GB) 1998-10-14 — — CN disclosed
EP-0841924-A1 BENZIMIDAZOLE COMPOUNDS NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) 1998-05-20 — — EP disclosed
WO-1997004771-A1 BENZIMIDAZOLE COMPOUNDS NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) 1997-02-13 — — WO disclosed
EP-0413415-A1 Carboxylic acids and derivates thereof The British Petroleum Company p.l.c. (GB) 1991-02-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11820720-B2 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deuteropiperidine-2,6-dione derivatives and compositions comprising and methods of using the same IL5, IL15, CXCR5 TDP1 2494/4885L3MBTL1 4416/4885TSHR 3742/4885
US-11419861-B2 Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases CRBN, UBQLN1, UBQLN2 TDP1 2037/4885L3MBTL1 1276/4885TSHR 4595/4885
US-10996215-B2 Methods for determining drug efficacy for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancers BCL9, BCL9L, IKZF1 TDP1 2470/4885L3MBTL1 1209/4885TSHR 4499/4885
US-20220003749-A1 METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS BCL9, BCL9L, IKZF1 TDP1 2470/4885L3MBTL1 1209/4885TSHR 4499/4885
US-11733233-B2 Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases CRBN, UBQLN1, UBQLN2 TDP1 2037/4885L3MBTL1 1276/4885TSHR 4595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.